



Ind-Swift Laboratories Limited

Registered Office

SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh – 160101 INDIA

✉ info@indswiftlabs.com

📞 0172-2730503, 2730920, 5061851-53

CIN No. L24232CH1995PLC015553

Ref: ISLL:CH:2026

Date: 31st January, 2026

The President
Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

The Vice President,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor
Plot No. C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

BSE Scrip Code: 532305

NSE Symbol: INDSWFTLAB

Subject: Outcome of the Board Meeting

Dear Sir/Ma'am,

Pursuant to Regulation 30, Regulation 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform you that the Board of Directors of the Company, at its meeting held today, i.e., Saturday, January 31, 2026, has, inter alia, considered and approved the following:

I. Standalone and Consolidated Un-Audited Financial Results of the Company for the quarter and nine months ended December 31, 2025, along with the Limited Review Reports issued by the Statutory Auditors.

A copy of the Financial Results together with the Limited Review Reports is enclosed herewith as **Annexure I**.

The said financial results shall also be made available on the Company's website at www.indswiftlabs.com/investor.

II. Based on the recommendations of the Nomination and Remuneration Committee and approval of the Audit Committee, **and subject to the approval of shareholders** (to be obtained in due course), the Board has approved the following restructuring/changes in the key positions of Board of Directors and Key Managerial Personnel of the Company, including approval of remuneration, effective February 1, 2026:

- Mr. Navrattan Munjal, Chairman and Managing Director has been re-designated to Chairman and Whole-Time Director with effect from February 01, 2026, for the period up to March 22, 2028.
- Mr. Himanshu Jain, Joint Managing Director has been appointed as the Managing Director (Domestic Operations) with effect from February 01, 2026, for the period up to March 22, 2028.

Manufacturing Facilities:

Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab – 140507

Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir - 184121

📞 0172-2730503, 2730920, 5061851-53 ✉ info@indswiftlabs.com 🌐 www.indswiftgroup.com

Follow us:



Ind-Swift Laboratories Limited

Registered Office

SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh – 160101 INDIA

✉ info@indswiftlabs.com

📞 0172-2730503, 2730920, 5061851-53

CIN No. L24232CH1995PLC015553

c) Mr. Sahil Munjal, Whole-Time Director has been appointed as Managing Director (Global Operations) with effect from February 01, 2026, for the period up to February 12, 2030.

III. Based on the recommendation of the Nomination and Remuneration Committee and approval of the Audit Committee, the Board has approved payment of remuneration to Mr. Rishav Mehta for the remaining period of his tenure, i.e., from March 23, 2026 to March 22, 2028, on the same terms and conditions as previously approved, subject to shareholder approval.

In Addition, The Company hereby informs that it is in the process of migrating its website from www.indswiftlabs.com to www.indswiflgroup.com. During the migration phase, all disclosures and announcements shall continue to be available at www.indswiftlabs.com/investor. The migration is expected to be completed by **March 31, 2026**.

The details required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (“Master Circular”) are attached as **Annexures**.

The Board Meeting commenced at 04:00 P.M and concluded at 06:00 P.M.

This is for your information and record.

Thanking you,

For IND-SWIFT LABORATORIES LTD.

PARDEEP VERMA
VP-CORPORATE AFFAIRS &
COMPANY SECRETARY



Manufacturing Facilities:

Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab – 140507

Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir - 184121

📞 0172-2730503, 2730920, 5061851-53 ✉ info@indswiftlabs.com 🌐 www.indswiflgroup.com

Follow us:

For verifying authenticity of this letter, please reach us by sending copy of same on hr.ho@indswiftlabs.com



RATTAN KAUR & ASSOCIATES
CHARTERED ACCOUNTANTS
SCF: 1, SECTOR: 20-C
CHANDIGARH: 160020
Mobile: 9501343300
Email: carattan@gmail.com

Independent Auditor's Review Report on the Standalone Unaudited Financial Results of Ind-Swift Laboratories Limited for the Quarter ended on December 31, 2025 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

To The Board of Directors of Ind-Swift Laboratories Ltd.

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of Ind-Swift Laboratories Limited for the Quarter and nine-month ended 31.12.2025, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 read with relevant rules, issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of Interim Financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on Auditing as specified under Section 143(10) of The Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





RATTAN KAUR & ASSOCIATES
CHARTERED ACCOUNTANTS
SCF: 1, SECTOR: 20-C
CHANDIGARH: 160020
Mobile: 9501343300
Email: carattan@gmail.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 (as of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rattan Kaur & Associates
Chartered Accountants
(Regd. No.: 022513N)



Rattan Kaur
(Partner)
M. No. 513530

Place: Chandigarh
Date: 31.01.2026
UDIN: 26513530HWYYFB9270



Ind-Swift
LABORATORIES LIMITED

One World. One Health. One Ind-Swift

IND SWIFT LABORATORIES LTD.

Ind-Swift Laboratories Limited

Registered Office

SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh - 160101 INDIA

✉ info@indswiftlabs.com

📞 0172-2730503, 2730920, 5061851-53

CIN No. L24232CH1995PLC015553

Regd Office : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160101

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31ST DEC 2025

CIN L24232CH1995PLC015553

Particulars	STANDALONE						Rs. In Lakhs
	Quarter Ended 31.12.2025	Quarter Ended 30.09.2025	Quarter Ended 31.12.2024	Nine month Ended 31.12.2025	Nine month Ended 31.12.2024	Year Ended 31.03.2025	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
Income from Operations:							
Revenue from operations	14948.10	15043.73	12154.21	44791.33	40490.04	54964.67	
Other Income	2757.87	1785.90	1663.36	6001.93	7686.22	8127.49	
Total Income	17705.98	16829.63	13817.57	50793.26	48176.25	63092.16	
EXPENSES:							
a. Cost of Materials Consumed	6613.95	6591.08	5069.13	19649.72	19278.55	22455.96	
b. Purchase of stock in Trade	984.53	1189.40	1377.22	3040.16	3689.25	7080.36	
c. (Increase) / decrease in FG, WIP & stock in trade	(585.69)	(56.55)	(864.33)	(826.90)	(1458.95)	(1036.23)	
d. Employee benefit	3139.22	3572.76	2912.70	9912.46	8454.77	11533.48	
e. Finance Costs	67.36	201.46	1002.72	383.95	2967.56	291.84	
f. Depreciation	883.52	697.75	581.22	2248.95	1704.21	2447.93	
g. Other expenditure	4256.24	3528.05	3752.54	11949.87	10473.64	16224.97	
TOTAL EXPENSES	15359.12	15723.95	13831.19	46358.20	45109.03	58998.31	
Profit/(loss) before exceptional items and Tax	2346.85	1105.68	(13.62)	4435.06	3067.22	4093.85	
Exceptional Items (Income) / loss	585.40	0.00	72.57	585.40	(732.46)	(22320.42)	
Profit/(loss) before Tax (After exceptional items)	1761.45	1105.68	(86.19)	3849.66	3799.68	26414.27	
Tax Expenses :-							
Current Tax	400.00	230.00	0.00	800.00	0.00	407.85	
Mat credit Utilisation	0.00	0.00	0.00	0.00	0.00	445.57	
Deferred Tax	0.00	0.00	0.00	0.00	0.00	(382.61)	
Income Tax Adjustment of Previous Years	287.27	0.00	0.00	287.85	0.00	334.93	
Profit/ (Loss) after tax and before share of	1074.18	875.68	(86.19)	2761.81	3799.68	25608.53	
Share of profit (loss) in joint venture	0.00	0.00	0.00	0.00	0.00	0.00	
Profit (+)/ Loss (-) for the period from continuing operations	1074.18	875.68	(86.19)	2761.81	3799.68	25608.53	
Profit (+)/ Loss (-) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	
Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	
Profit (+)/ Loss (-) from discontinuing operations (after Tax)	0.00	0.00	0.00	0.00	0.00	0.00	
Net Profit / (Loss) for the period after tax & Exceptional items	1074.18	875.68	(86.19)	2761.81	3799.68	25608.53	
Other Comprehensive Income							
A) Items that will not be reclassified to P/L A/c	0.00	0.00	0.00	0.00	0.00	0.00	
B) Items that will be reclassified into P/L A/c	0.00	0.00	0.00	0.00	0.00	(1722.55)	
Other Comprehensive Income (Loss) for the period, net of Tax	0.00	0.00	0.00	0.00	0.00	(1722.55)	
Total Comprehensive Income for the Period	1074.18	875.68	(86.19)	2761.81	3799.68	27331.08	
Paid up Equity Share Capital(Face Value of Rs. 10/- per Share)	8161.16	8161.16	5908.69	8161.16	5908.69	6874.36	
Reserve excluding revaluation reserves						116407.81	
EPS (of Rs. 10/- each) (Not annualised)							
Basic	1.32	1.10	-0.13	3.39	5.65	38.08	
Diluted	1.27	1.05	-0.12	3.27	5.15	36.00	

Date : 31.01.2026

Place : Chandigarh

For Ind Swift Laboratories Ltd.

NR MUNJAL

Chairman & Managing Director

Neerat



Manufacturing Facilities:

Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab – 140507

Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir - 184121

📞 0172-2730503, 2730920, 5061851-53 ✉ info@indswiftlabs.com 🌐 www.indswiftgroup.com

For verifying authenticity of this letter, please reach us by sending copy of same on hr.ho@indswiftlabs.com

Follow us:



RATTAN KAUR & ASSOCIATES
CHARTERED ACCOUNTANTS
SCF: 1, SECTOR: 20-C
CHANDIGARH: 160020
Mobile: 9501343300
Email: carattan@gmail.com

Independent Auditor's Review Report on Consolidated Unaudited Financial Results of Ind-Swift Laboratories Limited for the Quarter ended on December 31, 2025 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (as amended).

To The Board of Directors of Ind-Swift Laboratories Ltd

- 1) We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Ind-Swift Laboratories Ltd. ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), and its share of the Net Profit after Tax and Total Comprehensive Income of its Joint Ventures for the quarter ended 31.12.2025 ("the Statement") and consolidated year to date results from 01-04-2025 to 31-12-2025, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations")
- 2) This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matter, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4) The Statement includes the results of:

Particulars	Name
Subsidiary Companies	Ind Swift Laboratories Inc. USA Fortune (India) Constructions Ltd MJM Remedies Private Limited ISLL Middle East LLC-FZ Ind-Swift India Ltd (Kenya)
Joint Venture	Indis Healthcare LLP

5) Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6) We did not review the interim financial results, which have been prepared by the management, of 4 subsidiaries included in the unaudited consolidated financial results whose interim financial results reflect total revenue of Rs 524.76 Lakhs and Rs. 2112.66 Lakhs for the quarter and nine months ended 31.12.2025 respectively, total net profit / (loss) and total comprehensive Income/(Loss) of Rs (122.93) Lakhs and Rs. (141.53) Lakhs for the quarter and nine months ended 31.12.2025 respectively.

7) We did not review the interim financial statements/Financial information/Financial results of Indis Healthcare LLP (Joint Venture) whose interim financial statements/Financial information/Financial results reflect total Net Profit/ Loss of Rs. 1.82 lakhs and Rs. 9.15 lakhs for the quarter and nine months ended 31-12-2025 respectively.

Our conclusion on the Statement is not modified in respect of the above matter.

For Rattan Kaur & Associates
 Chartered Accountants

FRN: 022513N



Rattan Kaur
 (Partner)
 M. No. 513530

Place: Chandigarh
Date: 31.01.2026
UDIN: 26513530BYMMIY5118



One World. One Health. One Ind-Swift

Ind-Swift Laboratories Limited

Registered Office

SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh - 160101 INDIA

✉ info@indswiftlabs.com

📞 0172-2730503, 2730920, 5061851-53

CIN No. L24232CH1995PLC015553

IND SWIFT LABORATORIES LTD.

Regd Office : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160101


STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31ST DEC 2025

CIN L24232CH1995PLC015553

Particulars	CONSOLIDATED						Rs. In Lakhs
	Quarter Ended 31.12.2025	Quarter Ended 30.09.2025	Quarter Ended 31.12.2024	Nine month Ended 31.12.2025	Nine month Ended 31.12.2024	Year Ended 31.03.2025	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
Income from Operations:							
Revenue from operations	15085.34	15264.42	12879.86	45623.17	42411.78	56171.25	
Other Income	2757.87	1785.98	1663.55	6002.01	7692.33	8138.24	
Total Income	17843.21	17050.40	14543.41	51625.18	50104.11	64309.49	
EXPENSES:							
a. Cost of Materials Consumed	6603.39	6610.32	5654.35	19753.65	20858.50	22419.85	
b. Purchase of stock in Trade	984.53	1189.40	1377.22	3040.16	3689.25	7080.36	
c. (Increase) / decrease in FG, WIP & stock in trade	(563.85)	(34.71)	(864.33)	(695.89)	(1458.95)	(705.00)	
d. Employee benefit	3195.36	3627.06	2966.22	10075.55	8620.00	11752.09	
e. Finance Costs	67.37	201.46	1002.76	383.96	2967.65	291.93	
f. Depreciation	883.52	697.75	581.22	2248.95	1704.21	2447.93	
g. Other expenditure	4448.22	3724.81	4411.37	12524.38	11722.42	17562.89	
TOTAL EXPENSES	15618.52	16016.09	15128.81	47330.77	48103.08	60850.06	
Profit/(loss) before exceptional items and Tax	2224.69	1034.31	(585.40)	4294.41	2001.03	3459.43	
Exceptional items (income) / loss	585.40	0.00	72.57	585.40	(732.46)	(22320.42)	
Profit/(loss) before Tax (After exceptional items)	1639.29	1034.31	(657.97)	3709.01	2733.49	25779.85	
Tax Expenses :-							
Current Tax	400.00	230.00	(107.59)	800.00	(92.02)	328.85	
Mat credit Utilisation	0.00	0.00	0.00	0.00	0.00	445.57	
Deferred Tax	0.00	0.00	0.00	0.00	0.00	(382.34)	
Income Tax Adjustment of Previous Years	287.27	0.00	0.00	287.85	0.00	334.93	
Profit/ (Loss) after tax and before share of	952.01	804.31	(550.38)	2621.16	2825.51	25052.83	
Share of profit (loss) in joint venture	1.82	(5.29)	1.16	9.15	(4.74)	(5.17)	
Profit (+) / Loss (-) for the period from continuing operations	953.83	799.02	(549.22)	2630.31	2820.77	25047.66	
Profit (+) / Loss (-) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	
Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	
Profit (+) / Loss (-) from discontinuing operations (after Tax)	0.00	0.00	0.00	0.00	0.00	0.00	
Net Profit / (Loss) for the period after tax & Exceptional items	953.83	799.02	(549.22)	2630.31	2820.77	25047.66	
Other Comprehensive Income							
A) Items that will not be reclassified to P/L A/c	0.00	0.00	0.00	0.00	0.00	0.00	
B) Items that will be reclassified into P/L A/c	0.00	0.00	0.00	0.00	0.00	(1722.55)	
Other Comprehensive Income (Loss) for the period, net of Tax	0.00	0.00	0.00	0.00	0.00	(1722.55)	
Total Comprehensive Income for the Period	953.83	799.02	(549.22)	2630.31	2820.77	26770.21	
Paid up Equity Share Capital (Face Value of Rs. 10/- per Share)	8161.16	8161.16	5908.69	8161.16	5908.69	6874.36	
Reserve excluding revaluation reserves						117299.97	
EPS (of Rs. 10/- each) (Not annualised)							
Basic	1.17	1.00	-0.82	3.23	4.20	37.25	
Diluted	1.13	0.96	-0.75	3.11	3.83	35.21	

For Ind Swift Laboratories Ltd.

N R MUNJAL
Chairman & Managing Director



Date : 31.01.2026

Place : Chandigarh

Manufacturing Facilities:

Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab - 140507

Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir - 184121

📞 0172-2730503, 2730920, 5061851-53 ✉ info@indswiftlabs.com 🌐 www.indswiflgroup.com

For verifying authenticity of this letter, please reach us by sending copy of same on hr.ho@indswiftlabs.com

Follow us:

Notes: -

1. The above un-audited Standalone and Consolidated Financial Results have been prepared considering the requirements of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended. These results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 31st January, 2026.
2. The un-audited Standalone and Consolidated Financial Results for the quarter ended and nine months ended 31.12.2025 have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.
3. **The above un-audited Standalone and Consolidated Financial Results are results of the combined entity post Amalgamation of Ind Swift Limited with the Company:** The Board of Directors at its meeting held on 25th September, 2023 had approved a draft Scheme of Arrangement for Amalgamation of Ind-Swift Limited (“ISL/Transferor Company”) with Ind-Swift Laboratories Limited (“ISLL/Transferee Company”) and their respective shareholders and creditors under Section 230-232 of the Companies Act, 2013.

The Scheme of Amalgamation has been sanctioned by the Hon’ble NCLT, Chandigarh Bench on 17th July, 2025 and a certified copy of the scheme has been duly received on 28th July, 2025. Subsequently both the Transferor and Transferee Company have filed the E-form INC-28 with the Registrar of Companies, Chandigarh, on 8th August, 2025. Accordingly, the scheme became effective from 8th August, 2025 (“Effective Date”) and consequently ISL stands dissolved without being wound up. In accordance with the scheme the appointed date of the scheme is 31st March, 2024.

The record date for determining entitlement of shareholders of ISL to whom shares of ISLL were to be allotted in terms of the share exchange ratio was fixed for 14th August, 2025. Accordingly, ISLL has issued and allotted a total of 81,24,698 (Eighty-One Lakhs Twenty-Four Thousand Six Hundred and Ninety-Eight) equity shares to the eligible shareholders of ISL on 25th August, 2025.

During the quarter ended 31st December, 2025, the Company has received listing and trading approvals for the said equity shares from BSE Limited and National Stock Exchange of India Limited. The equity shares have been credited to the demat accounts of the eligible shareholders. Further, fractional entitlements, if any, have been settled by crediting the corresponding amounts directly to the respective shareholders’ bank accounts.

The Company has given effect to the amalgamation of Ind-Swift Limited with the Company using the pooling of interest method as specified by Appendix C to **Ind AS 103-“Business combination of entities under common control”**. Pursuant to the Amalgamation, as per the Ind AS principles, comparative balances have been restated in the standalone and consolidated financial results as per the appointed date viz. 31st March, 2024.

4. Exceptional items for the quarter ended 31st December, 2025 comprise of Rs. 585.40 Lakhs towards balances written back/written off (net) on account of amounts no longer payable/receivable.

Manufacturing Facilities:

Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab – 140507

Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir - 184121

📞 0172-2730503, 2730920, 5061851-53 ✉ info@indswifflabs.com 🌐 www.indswifflgroup.com

For verifying authenticity of this letter, please reach us by sending copy of same on hr.ho@indswifflabs.com



- On 27th June 2024, the Board of Directors had approved a preferential issue of 2,60,00,000 fully convertible warrants ("Warrants") at an issue price of Rs. 121/- per warrant, aggregating to Rs. 314.60 crore, to allottees from both the Promoter and Non-Promoter categories, subject to shareholder approval. The shareholders of the Company approved the aforesaid issue at their meeting held on 22nd July 2024, and subsequently, the Preferential Issue Committee of the Board, on 30th August 2024, allotted the 2,60,00,000 warrants upon receipt of 25% of the total issue consideration.

As on date a total of 1,44,00,000 warrants have been converted into the equity shares. No warrants were converted during quarter ended 31st December, 2025.

- The Company has invested the available surplus funds in various investment avenues which is regularly being monitored by the Investment Committee duly constituted by the Board of Directors of the Company.
- The Company had made investment in the 800 Non-Convertible Debentures (NCD) of M/s. Ashok Investors Trust Ltd with the face value of Rs. 5,00,000/- each. Out of these 40 debentures have been redeemed during the quarter.
- Pursuant to the terms of the Business Transfer Agreement (BTA), the Company had invested Rs. 48.00 crores in Series B unsecured, unlisted and non-convertible debentures of M/s. Synthimed Labs Private Limited. During the quarter, the said debentures were redeemed in full on 10th December 2025. The Company received an aggregate amount of Rs. 61.29 crores towards redemption of the debentures, comprising principal and interest, net of tax deducted at source (TDS).
- The Board of Directors had in the meeting held on 14th November, 2025, authorized investment of up to Rs. 51 Crores in the SEBI-registered AIFs. Out of this Rs. 51 Crores, during the quarter, a sum of Rs. 29.11 Crores has been invested in the AIF scheme floated by India Resurgence Fund under the name India Resurgence Fund II – Scheme I.
- The Consolidated financial results include the financial results of the parent company, Ind-Swift Laboratories Limited and the financial results of the following subsidiaries/Joint Venture:
 - Ind-Swift Laboratories Inc., USA (Subsidiary)
 - Fortune (India) Constructions Limited (Subsidiary)
 - Indis Healthcare LLP (Joint Venture)
 - MJM Remedies Private Limited (Subsidiary)
 - ISLL Middle East LLC-FZ (Subsidiary)
 - Ind Swift India Limited Kenya (Subsidiary)
 - Capital Strikers LLP (Joint Venture)
- Ind-Swift Laboratories Limited and its subsidiaries are collectively referred to as 'the Group'.
- No adjustment has been made in respect of Deferred Taxes as per IND AS-12, as the same would be provided at the year end.
- During the quarter under review the Company has not issued any Non-Convertible Debt Securities.
- The previous period figures have been re-grouped and re-classified wherever necessary.

Manufacturing Facilities:

Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab – 140507

Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir - 184121

📞 0172-2730503, 2730920, 5061851-53 ✉ info@indswiftlabs.com 🌐 www.indswiftgroup.com

For verifying authenticity of this letter, please reach us by sending copy of same on hr.o@indswiftlabs.com





Ind-Swift Laboratories Limited

Registered Office

SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh - 160101 INDIA

✉ info@indswiftlabs.com

📞 0172-2730503, 2730920, 5061851-53

CIN No. L24232CH1995PLC015553

14. The Company is exclusively in the Pharmaceutical Business segment.

Place: Chandigarh

Date: 31st January, 2026

For Ind Swift Laboratories Limited



N.R. Munjal

Chairman & Managing Director



Manufacturing Facilities:

Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab - 140507

Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir - 184121

📞 0172-2730503, 2730920, 5061851-53 ✉ info@indswiftlabs.com 🌐 www.indswiftgroup.com

Follow us:     

For verifying authenticity of this letter, please reach us by sending copy of same on hr.ho@indswiftlabs.com

Annexure-II

Details under Regulation 30 of Listing Regulations read SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

S. No.	Particulars	Details
1.	Name	Mr. Navrattan Munjal
2.	DIN	00015096
3.	Reason for change	Change in designation
4.	Designation	Chairman and Whole Time Director
5.	Date of Change	February 1, 2026
6.	Term of appointment	Redesignation shall be for the remainder of his term w.e.f. February 01, 2026 till March 22, 2028 subject to the approval of Shareholders.
7.	Brief profile (in case of appointment)	Mr. N.R. Munjal has served as the Chairman and Managing Director of the Ind-Swift Group and has over three decades of experience in the pharmaceutical industry. He has played a key role in defining the Group's long-term strategy, driving sustainable growth, and expanding its global presence across domestic and international markets. Under his leadership, the Group has strengthened its operations, governance framework, and international footprint. He provides strategic direction and guidance to the Board and senior management on matters relating to business development, operations, and corporate governance.
8.	Disclosure of relationships between Directors (in case of appointment of a director)	He is the father of Mr. Sahil Munjal (Director). Except this, he is not related to the any other Director(s)/KMP of the Company.
9.	Information as required under BSE circular Number LIST/COM/14/2018-19 dated June 20, 2018.	Mr. Navrattan Munjal is not debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other such authority.

Manufacturing Facilities:

Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab – 140507

Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir - 184121

☎ 0172-2730503, 2730920, 5061851-53 ✉ info@indswiftlabs.com 🌐 www.indswiftgroup.com

Follow us:     

Annexure-III

Details under Regulation 30 of Listing Regulations read SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

S No	Particulars	Details
1.	Name	Mr. Himanshu Jain
2.	DIN	00014533
3.	Reason for change	Change in designation
4.	Designation	Managing Director (Domestic Operations)
5.	Date of Change	February 1, 2026
6.	Term of appointment	Appointment shall be for the remainder of his term w.e.f. February 01, 2026 till March 22, 2028 subject to the approval of Shareholders.
7.	Brief profile (in case of appointment)	Mr. Himanshu Jain has over 19 years of experience in the pharmaceutical industry with expertise in operations, project planning, financial strategy, and business management. He has played a key role in driving the Company's domestic business, including sales, manufacturing, supply chain, and operational performance. He has been instrumental in strengthening internal controls, operational efficiency, and business expansion across India. He provides strategic and operational leadership in execution of the Company's domestic growth strategy.
8.	Disclosure of relationships between Directors (in case of appointment of a director)	Mr. Himanshu Jain is not related to any other Director of the Company
9.	Information as required under BSE circular Number LIST/COM/14/2018-19 dated June 20, 2018.	Mr. Himanshu Jain is not debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other such authority.

Manufacturing Facilities:

Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab – 140507

Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir - 184121

📞 0172-2730503, 2730920, 5061851-53 ✉ info@indswiftlabs.com 🌐 www.indswiftgroup.com

Follow us:     

Annexure-IV

Details under Regulation 30 of Listing Regulations read SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

S No	Particulars	Details
1.	Name	Mr. Sahil Munjal
2.	DIN	00015407
3.	Reason for change	Change in designation
4.	Designation	Managing Director (Global Operations)
5.	Date of Change	February 1, 2026
6.	Term of appointment	Appointment shall be for the remainder of his term w.e.f. February 01, 2026 till February 12, 2030 subject to the approval of Shareholders.
7.	Brief profile (in case of appointment)	Mr. Sahil Munjal has over 18 years of experience in the pharmaceutical industry with expertise in global business operations, information technology systems, and international coordination. He has been associated with the Ind-Swift Group since July 1, 2004, and has played a key role in strengthening the Company's global business, including contract manufacturing, out-licensing, co-development partnerships, and formulation supply solutions. He provides leadership in export operations, international business development, and coordination with global stakeholders.
8.	Disclosure of relationships between Directors (in case of appointment of a director)	Mr. Sahil Munjal is Son of Mr. Navrtan Munjal (Director). Except this, he is not related to any other Director(s)/KMP of the Company.
9.	Information as required under BSE circular Number LIST/COM/14/2018-19 dated June 20, 2018.	Mr. Sahil Munjal is not debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other such authority.

Manufacturing Facilities:

Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab – 140507

Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir - 184121

☎ 0172-2730503, 2730920, 5061851-53 ✉ info@indswiftlabs.com 🌐 www.indswiftgroup.com

Follow us:     

**Ind-Swift Laboratories Limited***Registered Office*

SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh – 160101 INDIA

✉ info@indswiftlabs.com

📞 0172-2730503, 2730920, 5061851-53

CIN No. L24232CH1995PLC015553

Annexure-V**Details under Regulation 30 of Listing Regulations read SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024**

S No	Particulars	Details
1.	Name	Mr. Rishav Mehta
2.	DIN	03028663
3.	Reason for disclosure	Approval of remuneration for remaining tenure
4.	Designation	Whole-Time Director
5.	Period of remuneration	March 23, 2026 to March 22, 2028
6.	Nature of approval	Board has based on recommendations of Nomination & Remuneration Committee and Audit Committee, approved the remuneration of Mr. Rishav Mehta for a period starting from March 23, 2026 up to March 22, 2028 and the same shall be subject to the approval of shareholders.
7.	Terms of remuneration	Same terms and conditions as previously approved

Manufacturing Facilities:

Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab – 140507

Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir - 184121

📞 0172-2730503, 2730920, 5061851-53 ✉ info@indswiftlabs.com 🌐 www.indswiflgroup.com

Follow us:

For verifying authenticity of this letter, please reach us by sending copy of same on hr.ho@indswiftlabs.com